Healthcare's
missing
intelligence.
The operating system that tells a medical practice what to do, when to do it, and exactly how to make money doing it. Then does it all for them. Automatically. Forever.
At a 12× exit multiple, Saara fetches a billion-dollar valuation. Seed investors get a piece of that — starting right now at a $7.5M pre-money.
The June update is out.
The window is real.
OSH360 term sheet advancing. Platform redesign live. Seed round building. The $7.5M pre-money closes when the term sheet executes — measured in weeks, not months.
330,000 practices.
Zero playbook.
Physicians receive zero business training and no on-the-job clinical guidance — then spend the next 30 years running million-dollar operations under one of the most complex regulatory environments on earth.
The tools exist. EHRs. Billing software. Scheduling apps. Compliance platforms. Practices use seven or more — and none of them talk to each other, none enforce the rules, and none tell the doctor what to do or execute anything for them.
That's the gap. That's Saara.
of every clinical day lost to administrative work — not patients
of insurance claim denials are entirely preventable
lost annually to operational failures no one has solved
One operating system.
Everything it needs to run.
Not an EHR. Not a chatbot. Not another point solution with a sales rep attached.
Saara sits above a clinic's existing software stack, connects everything, and actively runs the business — compliance, revenue, clinical workflow, supply chain, and staff protocols. All live. All connected. All enforcing the same standard of care, automatically.
A voice-driven LLM interface sits atop the entire organization — front office, back office, finance, compliance, billing. Integrated with Medicare, EHR, GPO, CMS-1500, and ambient clinical documentation. HIPAA-compliant by design, not retrofit.
The compliance backbone? Every protocol reviewed by our Senior Advisory Panel — Liaison to the AMA CPT® Editorial Panel, advisor to AMA, CMS, and the World Health Organization. The people who helped write the very rules Saara enforces. That’s not a feature. That's a structural moat.
Practices don't just get better systems. They get confidence.
The numbers
don't need translation.
Seven real practices. Real results. Zero red flags, audit-ready documentation across all Saara protocols to date.
reduction in compliance errors across all pilot practices
faster clinical protocol rollout from day-one baseline
average margin lift across active pilot practices
Four revenue streams.
All compounding.
SaaS Subscriptions
Tiered pricing starting at $850/month. Recurring, predictable, scales automatically with practice growth. Three tiers: Starter, Growth, Enterprise — each with expanding module access.
Saara Studio Marketplace
Zero-activation-fee protocol marketplace. One-click add-ons. Network effects compound as the library grows — every new protocol makes the platform more valuable to every existing customer.
Documentation & Add-Ons
High-margin add-ons: ambient documentation, CMS-1500 automation, clinical coding. Clear standalone value, strong willingness to pay, and industry-leading retention once adopted.
Supply Chain Commissions
8–12% supplier-side commission — invisible to customers, who save 15–30% through our GPO network. Saara earns the spread. Practices often recoup their entire subscription cost from GPO savings alone.
Saara Studio.
The only marketplace where a practice can activate a new service line — instantly.
No implementation consultants. No six-month rollouts. No guesswork. A wound care practice adds a hormone optimization protocol in a click. A podiatry group launches a regenerative medicine line over a weekend. New revenue stream. Zero-friction on-ramp.
Every protocol has been clinically validated and reviewed by our Senior Advisory Panel — Liaison to the AMA CPT® Editorial Panel, advisor to AMA, CMS, and the World Health Organization. Zero shortcuts. Maximum confidence.
The depth of experience
this problem demands.
People who have built products used by billions, managed global healthcare at the highest level, and spent decades inside the exact problem Saara solves don't join companies they don't believe in.
Engineering & Product
Saara's technical team is drawn from the engineering and design organizations of the world's most-used platforms. Hamza Shaikh — lead designer for Google G-Suite (Gmail, Drive, Docs, Meet) and founding designer of a $1B AI unicorn — leads product design. That's not an accident. It's a deliberate decision about what Saara will become.
Sean Filson (CEO) scaled a medical services organization to a $1.25B portfolio — front office, back office, compliance, billing, supply chain. All of it. Jeff Igoe (Co-Founder) has operated functional medicine clinics for 12+ years and built a digital agency supporting hundreds of practices. These founders have lived inside this problem every single day.
"If nobody's going to build the operating tool of our dreams, do you think we could build it?" — Sean Filson, in the conversation that started Saara.
Board of Directors
Issue #2 is out. Read what happened this month.
OSH360 advancing. Platform shipped. Seed window closing. The full picture is in Issue #2.
Senior Advisory Panel — Liaison to the AMA CPT® Editorial Panel, advisor to AMA, CMS, and the World Health Organization. The people who helped write the billing rules and CPT codes Saara enforces. Compliance isn’t a feature here — it’s a structural moat. Full bios and references available to qualified investors under NDA.
One of the last
untransformed industries.
Healthcare is where technology comes to die — or, for the right company, to dominate for a decade. Saara is entering at the inflection point with proven traction and a team that's been inside the problem for years.
U.S. Physician Groups market (2024)
Private specialty practices in the U.S. / 4.2M providers
MSO Market by 2034 — 8.85% CAGR
CAGR in PE-backed medical networks (2024–2032)
Conservative.
Then it gets interesting.
| Year | Pro Forma Revenue | Model Revenue |
|---|---|---|
| 2026 | $3.8M | $1.6M |
| 2027 | $21.4M | $14.3M |
| 2028 Convergence | $46.2M | $44.1M |
| 2029 | $70.8M | $85.1M |
| 2030 | $94.4M | $133.8M |
| 2032 | $142M | $242M |
Model converges with Pro Forma by 2028 — then significantly exceeds from 2029 onward as per-provider fees, enterprise mix, and marketplace revenue compound. Projected break-even: ~9 months post-MVP. All projections are illustrative. See legal disclaimer.
Doors just opened.
We are raising $3M to deliver the MVP, scale the first 50 practice accounts, and prove the model at a level that makes future rounds straightforward — if required at all.
Preferred Equity
post-MVP
Use of Funds — $3M Seed Round
A final tranche of pre-seed convertible notes is also available (2% interest, $5M cap). Minimum check size of $250K for the seed round. Pre-seed available at $100K minimums. Some accredited investors elect to straddle — allocating at both Pre-Seed and Seed.
How we think
about risk.
Sophisticated investors are better served by an honest framing of risk than a one-sided pitch.
Execution risk in healthcare AI
Healthcare AI is complex and regulated — execution failures are common and costly.
Our Senior Advisory Panel’s involvement is structural, not decorative. HIPAA-compliant by design. Seven completed pilots with zero compliance failures.
Long enterprise sales cycles
Provider settings are notoriously slow to adopt new technology, extending time-to-revenue.
Saara integrates via HL7/FHIR with nearly every major EHR — dramatically shortening deployment. Connect Internal Medicine went from signed to fully integrated in six weeks.
Capital intensity of healthcare GTM
Healthcare go-to-market is expensive and undercapitalized companies frequently stall before scale.
Capital-efficient model. Milestone-based path: Pre-Seed → Seed → subsequent priced rounds. Each round sized to commercial milestones — not arbitrary runway targets.
Technology risk in a shifting space
Top engineers are competed for daily and the LLM landscape shifts fast.
Saara's edge is not technology — it's the proprietary clinical protocols curated by our team, board, and advisors. Competitors can buy tech. They cannot buy our domain depth.
Why they can't copy this.
And they've tried.
The healthcare tech market is crowded with point solutions. Here is why Saara is structurally different — and why incumbents cannot close the gap by adding features.
The protocol library is the moat
Our Senior Advisory Panel includes the Liaison to the AMA CPT® Editorial Panel — the person who helps write the CPT codes that govern how medicine is billed in the United States. These protocols — and the network of advisors behind them — cannot be purchased, hired, or replicated by a competitor. The compliance library compounds in value every time a new specialty is added, every time a code changes, every time CMS updates its guidelines.
The GPO network is a distribution channel, not a feature
Patrick Hannigan’s 20 years of supply-chain operator relationships give Saara something no software competitor has: a GPO distribution network into 300,000 private practices. The GPO relationship creates immediate ROI that makes the software subscription free in comparison. Competitors cannot buy this access. It was earned through decades of operator trust.
The exit path is written into the architecture
Every major healthcare incumbent — Epic, Oracle Health, Optum, PE-backed MSO roll-ups — needs what Saara is building. An intelligent operating layer for specialty practices. The Saara Studio protocol marketplace creates a proprietary data asset that grows more valuable with every practice onboarded. At a 12× revenue exit multiple, the path to a billion-dollar outcome is a model outcome — not an outlier.
The window is 18 months.
GPT-4 opened a door. Every incumbent healthcare vendor is now scrambling to bolt AI onto a 20-year-old infrastructure. The practices adopting now are locking in operating systems, not features. The founders building now — with operator DNA, AMA-level compliance authority, and hospital-system supply-chain access — are the ones who will own this market. That window closes when the incumbents catch up. It hasn't closed yet.
Before you look at the entry table — read Issue #2.
The OSH360 term sheet changes the picture. The price at signing moves. The full context is in the update.
Two ways to enter Saara.
Some accredited investors elect to straddle — allocating at both Pre-Seed and Seed, balancing maximum entry leverage with preferred-stock protections.
| Term |
Pre-Seed Note
Max leverage
|
Seed Round
Preferred stock
|
|---|---|---|
| Valuation | $5M cap | $7.5M pre-money |
| Security | Convertible Note → Common | Preferred Stock |
| Minimum check | $100K | $250K |
| Liquidation preference | None (common) | 1× non-participating |
| Best suited for | Angels seeking maximum entry leverage | Investors prioritizing preferred status & information rights |
Ready to go deeper?
Let's talk.
Saara is raising $3M from a small group of aligned investors. Allocations are limited and moving. If you're interested in learning more, Sean will walk you through the full model, cap table, and pilot results personally — no deck required.
Scaled a medical services organization to a $1.25B portfolio. Built the operational systems that Saara now automates. He's been inside this problem for 20+ years.
Typically responds within a few hours. Or send a message directly →
Get the full package.
Detailed cap table, full financial model, return scenarios, advisory panel bios, product demo access, and full subscription documents — available to qualified investors under NDA.
Or reach out directly
Email Sean directlyRequest the investor deck
Request received.
Sean will be in touch within 24 hours with the full diligence package.
Send a direct emailLegal Disclaimers
This document and all content on this page are provided for informational purposes only in connection with a private offering of securities to accredited investors. It is not an offer to sell or a solicitation to buy securities.
Forward-looking statements carry inherent uncertainty. All financial scenarios, projections, and timelines are illustrative — not guaranteed outcomes. Actual results will differ materially based on company performance, market conditions, timing, and other factors beyond the Company's control.
Pre-seed and seed-stage investments carry substantial risk, including total loss of capital. This is not a suitable investment for all accredited investors. Future financings will dilute current ownership. There is no guarantee of any exit event, liquidity, or return.
No representation or warranty is made as to the accuracy of forward-looking statements. Consult your own legal, tax, and financial advisors before making any investment decision.
Saara Intelligence Corporation is a Wyoming C-Corporation. This material is confidential and intended for accredited investors only. Reproduction or distribution without written consent is prohibited.